Skip to main content
. 2020 Aug 3;6(10):FSO608. doi: 10.2144/fsoa-2020-0070

Table 3. . Immunotherapy treatment toxicity.

Toxicity Number (% of total cohort) Number with eosinophilia (% of column 2)
Any grade 66 (46.6) 19 (28.7)
Grade 3 or 4 15 (10.5) 3 (20)

Immune related adverse events occurred in 47% of patients, with 10% experiencing severe (grade 3 or 4) toxicity. There was a significant association found between eosinophilia on treatment and the development of toxicity of any grade (p = 0.042), but not with severe toxicity.